Patents by Inventor Kambiz YADIDI

Kambiz YADIDI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Dry powder formulations and methods of use
    Patent number: 11865210
    Abstract: The subject technology relates generally to pulmonary delivery of NSAIDs, such as aspirin.
    Type: Grant
    Filed: December 11, 2018
    Date of Patent: January 9, 2024
    Assignee: VECTURA INC.
    Inventor: Kambiz Yadidi
  • Treating inflammation with inhaled aspirin
    Patent number: 11819569
    Abstract: The subject technology relates generally to pulmonary delivery of NSAIDs, such as aspirin.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: November 21, 2023
    Assignee: VECTURA INC.
    Inventor: Kambiz Yadidi
  • DRY POWDER FORMULATIONS FOR INHALATION
    Publication number: 20230277450
    Abstract: A respirable dry powder including acetylsalicylic acid in particles has a mass median aerodynamic diameter (MMAD) within a range of about 0.5 µm to about 10 µm. The respirable dry powder may contain a pharmaceutically acceptable excipient, such as a phospholipid, in an amount ranging from about 0.1% (w/w) to about 10% (w/w) of the particles.
    Type: Application
    Filed: January 31, 2023
    Publication date: September 7, 2023
    Applicant: Vectura Inc.
    Inventor: Kambiz YADIDI
  • DRY POWDER FORMULATIONS FOR INHALATION
    Publication number: 20230218643
    Abstract: A respirable dry powder can include acetylsalicylic acid in particles having a mass median aerodynamic diameter (MMAD) within a range of about 0.5 ?m to about 10 ?m. The respirable dry powder may contain a pharmaceutically acceptable excipient, such as an amino acid (e.g., Leucine), in an amount ranging from about 0.1% (w/w) to about 40% (w/w) of the particles.
    Type: Application
    Filed: February 27, 2023
    Publication date: July 13, 2023
    Inventor: Kambiz YADIDI
  • Dry powder formulations for inhalation
    Patent number: 11596603
    Abstract: A respirable dry powder including acetylsalicylic acid in particles has a mass median aerodynamic diameter (MMAD) within a range of about 0.5 ?m to about 10 ?m. The respirable dry powder may contain a pharmaceutically acceptable excipient, such as a phospholipid, in an amount ranging from about 0.1% (w/w) to about 10% (w/w) of the particles.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: March 7, 2023
    Assignee: Vectura Inc.
    Inventor: Kambiz Yadidi
  • DRY POWDER FORMULATIONS FOR INHALATION
    Publication number: 20220040206
    Abstract: A respirable dry powder can include acetylsalicylic acid in particles having a mass median aerodynamic diameter (MMAD) within a range of about 0.5 ?m to about 10 ?m. The respirable dry powder may contain a pharmaceutically acceptable excipient, such as an amino acid (e.g., Leucine), in an amount ranging from about 0.1% (w/w) to about 40% (w/w) of the particles.
    Type: Application
    Filed: October 24, 2021
    Publication date: February 10, 2022
    Inventor: Kambiz Yadidi
  • DRY POWDER COMPOSITIONS WITH MAGNESIUM STEARATE
    Publication number: 20220016030
    Abstract: A stable dry powder composition for inhalation includes acetylsalicylic acid in particles having a mass median aerodynamic diameter (MMAD) in a range of about 1 ?m to about 5 ?m. The dry powder composition may contain a pharmaceutically acceptable excipient, such as a stearate, in an amount ranging from about 0.04% (w/w) to about 0.06% (w/w), or from about 0.4% (w/w) to about 0.6% (w/w), of the composition.
    Type: Application
    Filed: August 1, 2021
    Publication date: January 20, 2022
    Inventor: Kambiz Yadidi
  • Dry powder formulations for inhalation
    Patent number: 11160815
    Abstract: A respirable dry powder can include acetylsalicylic acid in particles having a mass median aerodynamic diameter (MMAD) within a range of about 0.5 ?m to about 10 ?m. The respirable dry powder may contain a pharmaceutically acceptable excipient, such as an amino acid (e.g., Leucine), in an amount ranging from about 0.1% (w/w) to about 40% (w/w) of the particles.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: November 2, 2021
    Assignee: OTITOPIC INC.
    Inventor: Kambiz Yadidi
  • Dry powder compositions with magnesium stearate
    Patent number: 11077058
    Abstract: A stable dry powder composition for inhalation includes acetylsalicylic acid in particles having a mass median aerodynamic diameter (MMAD) in a range of about 1 ?m to about 5 ?m. The dry powder composition may contain a pharmaceutically acceptable excipient, such as a stearate, in an amount ranging from about 0.04% (w/w) to about 0.06% (w/w), or from about 0.4% (w/w) to about 0.6% (w/w), of the composition.
    Type: Grant
    Filed: February 2, 2019
    Date of Patent: August 3, 2021
    Assignee: OTITOPIC INC.
    Inventor: Kambiz Yadidi
  • DRY POWDER FORMULATIONS FOR INHALATION
    Publication number: 20210186871
    Abstract: A respirable dry powder including acetylsalicylic acid in particles has a mass median aerodynamic diameter (MMAD) within a range of about 0.5 ?m to about 10 ?um. The respirable dry powder may contain a pharmaceutically acceptable excipient, such as a phospholipid, in an amount ranging from about 0.1% (w/w) to about 10% (w/w) of the particles.
    Type: Application
    Filed: August 7, 2020
    Publication date: June 24, 2021
    Inventor: Kambiz Yadidi
  • Antibiotic compositions for nasal irrigation and methods
    Patent number: 10849909
    Abstract: Provided herein are pharmaceutical formulations, nasal irrigation fluids, sachets, kits and the like comprising cephalosporin antibiotics, as well as methods of topical treatment of sinusitis and related conditions, methods of delivery of the formulations and fluids to the sinuses, methods of coating the sinuses, and methods of disruption and/or penetration of biofilms in the sinuses.
    Type: Grant
    Filed: August 13, 2019
    Date of Patent: December 1, 2020
    Assignee: RHINONASE, INC.
    Inventors: Kambiz Yadidi, Amanda Quiroga, Jagdeep Shur, Jeffrey B. Harris
  • Dry powder inhalation device
    Patent number: 10813881
    Abstract: Delivery of a dry powder via inhalation can be performed using an inhalation device having an inhalation tube and a hollow extension housing an assembly of components including a plurality of impellers, a puncturing device, and a dry powder container. The delivery of dry powder through the inhalation device is facilitated by the puncturing device puncturing the dry powder container, the impellers directing air flow, and the configuration of the extension and inhalation tube.
    Type: Grant
    Filed: September 13, 2017
    Date of Patent: October 27, 2020
    Assignee: OTITOPIC INC.
    Inventor: Kambiz Yadidi
  • Inhaled aspirin and magnesium to treat inflammation
    Patent number: 10786456
    Abstract: A stable dry powder composition for inhalation includes acetylsalicylic acid in particles having a mass median aerodynamic diameter (MMAD) in a range of about 1 ?m to about 5 ?m. The dry powder composition may contain a pharmaceutically acceptable excipient, such as a stearate, in an amount ranging from about 0.04% (w/w) to about 0.06% (w/w), or from about 0.4% (w/w) to about 0.6% (w/w), of the composition.
    Type: Grant
    Filed: April 26, 2019
    Date of Patent: September 29, 2020
    Assignee: OTITOPIC INC.
    Inventor: Kambiz Yadidi
  • Dry powder formulations for inhalation
    Patent number: 10772832
    Abstract: A respirable dry powder including acetylsalicylic acid in particles has a mass median aerodynamic diameter (MMAD) within a range of about 0.5 ?m to about 10 ?m. The respirable dry powder may contain a pharmaceutically acceptable excipient, such as a phospholipid, in an amount ranging from about 0.1% (w/w) to about 10% (w/w) of the particles.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: September 15, 2020
    Assignee: OTITOPIC INC.
    Inventor: Kambiz Yadidi
  • DRY POWDER FORMULATIONS FOR INHALATION
    Publication number: 20200121698
    Abstract: A respirable dry powder can include acetylsalicylic acid in particles having a mass median aerodynamic diameter (MMAD) within a range of about 0.5 ?m to about 10 ?m. The respirable dry powder may contain a pharmaceutically acceptable excipient, such as an amino acid (e.g., Leucine), in an amount ranging from about 0.1% (w/w) to about 40% (w/w) of the particles.
    Type: Application
    Filed: December 17, 2019
    Publication date: April 23, 2020
    Inventor: Kambiz Yadidi
  • Dry powder formulations for inhalation
    Patent number: 10568894
    Abstract: A respirable dry powder can include acetylsalicylic acid in particles having a mass median aerodynamic diameter (MMAD) within a range of about 0.5 ?m to about 10 ?m. The respirable dry powder may contain a pharmaceutically acceptable excipient, such as an amino acid (e.g., Leucine), in an amount ranging from about 0.1% (w/w) to about 40% (w/w) of the particles.
    Type: Grant
    Filed: June 2, 2017
    Date of Patent: February 25, 2020
    Assignee: OTITOPIC INC.
    Inventor: Kambiz Yadidi
  • ANTIBIOTIC COMPOSITIONS FOR NASAL IRRIGATION AND METHODS
    Publication number: 20200030336
    Abstract: Provided herein are pharmaceutical formulations, nasal irrigation fluids, sachets, kits and the like comprising cephalosporin antibiotics, as well as methods of topical treatment of sinusitis and related conditions, methods of delivery of the formulations and fluids to the sinuses, methods of coating the sinuses, and methods of disruption and/or penetration of biofilms in the sinuses.
    Type: Application
    Filed: August 13, 2019
    Publication date: January 30, 2020
    Inventors: Kambiz Yadidi, Amanda Quiroga, Jagdeep Shur, Jeffrey B. Harris
  • DRY POWDER COMPOSITIONS WITH MAGNESIUM STEARATE
    Publication number: 20190336448
    Abstract: A stable dry powder composition for inhalation includes acetylsalicylic acid in particles having a mass median aerodynamic diameter (MMAD) in a range of about 1 ?m to about 5 ?m. The dry powder composition may contain a pharmaceutically acceptable excipient, such as a stearate, in an amount ranging from about 0.04% (w/w) to about 0.06% (w/w), or from about 0.4% (w/w) to about 0.6% (w/w), of the composition.
    Type: Application
    Filed: February 2, 2019
    Publication date: November 7, 2019
    Inventor: Kambiz YADIDI
  • INHALED ASPIRIN AND MAGNESIUM TO TREAT INFLAMMATION
    Publication number: 20190321296
    Abstract: A stable dry powder composition for inhalation includes acetylsalicylic acid in particles having a mass median aerodynamic diameter (MMAD) in a range of about 1 ?m to about 5 ?m. The dry powder composition may contain a pharmaceutically acceptable excipient, such as a stearate, in an amount ranging from about 0.04% (w/w) to about 0.06% (w/w), or from about 0.4% (w/w) to about 0.6% (w/w), of the composition.
    Type: Application
    Filed: April 26, 2019
    Publication date: October 24, 2019
    Inventor: Kambiz YADIDI
  • Antibiotic compositions for nasal irrigation and methods
    Patent number: 10420776
    Abstract: Provided herein are pharmaceutical formulations, nasal irrigation fluids, sachets, kits and the like comprising cephalosporin antibiotics, as well as methods of topical treatment of sinusitis and related conditions, methods of delivery of the formulations and fluids to the sinuses, methods of coating the sinuses, and methods of disruption and/or penetration of biofilms in the sinuses.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: September 24, 2019
    Assignee: RHINONASE, INC.
    Inventors: Kambiz Yadidi, Amanda Quiroga, Jagdeep Shur, Jeffrey B. Harris